Hayden E. Klein

The Thyme Care virtual navigation program demonstrated a $594 reduction in total costs per member per month for navigated cancer patients compared with a control group, emphasizing the scalability of the independent virtual navigation model across various contracts, with opportunities to adapt to different populations and needs in the evolving landscape of value-based care arrangements.

Most patients in the cohort received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for first-line therapy; hospitalization was prevalent; and average medical and pharmacy costs were more than $140,000 per patient per year.

Aside from semaglutide, alternate weight loss routes include other anti-obesity medications, chronic weight management programs, or obesity medicine specialists, said Ian Neeland, MD.

Breastfeeding infants during the first 3 months can lower their risk of childhood obesity, regardless of the mother's body mass index before pregnancy.

Despite there being more patients undergoing bariatric surgery since the Affordable Care Act (ACA) was enacted in 2010, these surgeries had better postoperative outcomes.

Ian Neeland, MD, of University Hospitals Harrington Heart & Vascular Institute, talks about the uptick in patients at his practice seeking semaglutide for weight loss.

Especially during shortages, Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, director of pharmacy services at Minnesota Oncology, says practices should carve out areas where going to a different therapeutic approach isn't considered off-pathway.

Amrish Selvam is a fourth-year medical student at the University of Pittsburgh whose research and career interests lay in ophthalmology and who volunteers with the UPMC Vision Institute’s mobile eye clinic, the eyeVan.

Possible long-term consequences for patients with diabetes forced to switch to alternative medications during the semaglutide shortage include the risk of losing ground in glycemic control, having uncontrolled diabetes with associated symptoms, and other adverse events.

Edward "Ted" Arrowsmith, MD, MPH, medical director for pathways at OneOncology and managing partner at Tennessee Oncology, talks about challenges and changes in clinical pathways and the importance of keeping them updated.

A social-impact startup, Pittsburgh-based Fabric Health is adept at using community engagement to help members and their families navigate the complex world of health care—meeting customers where they are at, knowing time is often their most valuable resource.

According to Ian Neeland, MD, there are 2 main reasons for the shortage of injectable semaglutide: the fact that oral semaglutide has not yet been tested for weight loss, and that most practitioners just overlook it as an option.

Ian Neeland, MD, highlights that oral semaglutide is more accessible and that patients should avoid switching drug types during the shortage.

Melinda C. Aldrich, PhD, MPH, associate professor in the departments of medicine, thoracic surgery, and biomedical informatics at Vanderbilt University, discussed recently updated lung screening guidelines from the American Cancer Society and the importance of equity across populations as new guidelines are developed.

In this interview with Katie Cecconi, community service program coordinator at the UPMC Vision Institute, we learn more about the institute’s mobile eye care initiatives and how its services are working to overcome care equity gaps.

Ian Neeland, MD, of University Hospitals Harrington Heart & Vascular Institute, describes challenges patients with diabetes face during the semaglutide shortage and alternative options he gives his patients to prevent therapy disruptions.

Two major trials presented at the European Society of Cardiology (ESC) 2023 Congress were the STEP-HFpEF and FRAIL-AF trials.

Our most-viewed videos include interviews about a type 2 diabetes reversal program with impressive 6-month results, concerns over service denials in certain health plans, the Enhancing Oncology Model, and more.

The top 5 most-viewed content from the American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular Disease (CVD) Prevention included interviews with Stephen Nicholls, PhD, MBBS, and Emelia J. Benjamin, MD, ScM, as well as coverage on multiple areas of cardiovascular medicine.

The top 5 most-viewed heart failure (HF) content of the year focused on how walking can improve HF outcomes, a link between HF and carpal tunnel syndrome, and more.

Asian and Hispanic patients with stage II or III noncardia gastric adenocarcinoma had significantly better overall survival following surgery compared with their White counterparts.

In September, The American Journal of Managed Care® joined 4 individuals whose involvement with UPMC Health Plan, a Strategic Alliance Partner of AJMC®, has proved to be instrumental in furthering health equity and providing high-quality care in Pennsylvania, Ohio, West Virginia, and Maryland.

Our most-viewed cardiovascular content includes research showing that a heart-healthy diet lowers cardiovascular disease risk by 30%; an interview with Stephen Nicholls, PhD, MBBS, on the SURPASS-CVOT trial; and more.

An in-depth look into what the drug is being used for and what has contributed to the shortage.

Our top conference coverage of 2023 covered a range of topics, including cardiovascular disease, heart failure, breast cancer, and chronic lymphocytic leukemia.

Our most-read articles on diabetes covered racial biases in type 2 diabetes risk prediction models, cardiovascular disease as a leading cause of hospital admissions in patients with diabetes, and much more.

David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure, shared that the organization is able to reduce clinical trial costs to $1 to $5 million per drug trial, and that clinical trials are not always necessary to expand a drug's indication.

Our most-read coverage of American Society of Nephrology Kidney Week 2023 highlighted discussions on the challenges of medication dose adjustments in chronic kidney disease, the impact of LGBTQ+ health care disparities on kidney outcomes, and much more.